Skip to main content
. Author manuscript; available in PMC: 2017 Nov 21.
Published in final edited form as: J Mol Med (Berl). 2014 May 23;92(7):697–707. doi: 10.1007/s00109-014-1165-y

Table 3.

ALK TKIs in the clinic

ALK inhibitors (reference) ROS1 activity Status NCT identifier
Crizotinib [68, 69, 76] Yes Approved for ALK-positive NSCLC; investigational for ROS1 NCT00585195
Ceritinib (LDK378) [77] Yes Phase II/III NCT01828099, NCT01828112
Alectinib (CH5424802) [78, 79] No Phase I/II NCT01588028
AP26113 [80] Yes Phase I/II NCT01449461
ASP3026 [81] Yes Phase I NCT01284192

Modified from Brahmer et al. [82]